EIT Health and the EDIT-B consortium transform bipolar disorder diagnosis with groundbreaking blood test

World Mental Health Day is a reminder that timely, accurate diagnosis can change lives. For those living with bipolar disorder, the stakes could not be higher: studies show it takes more than 8 years on average to receive a correct diagnosis. Today, EIT Health and the EDIT-B consortium celebrate the success of their European multicentric clinical validation study. EDIT-B®, powered by RNA editing biomarkers and artificial intelligence, is the first-in-class diagnostic tool capable of differentiating bipolar depression from unipolar depression in adults.

By reducing diagnostic delays, EDIT-B® has the potential to improve care, prevent unnecessary suffering, and reduce costs to health systems. This milestone demonstrates the impact of strong collaboration between Europe’s leading researchers, clinicians, and innovators.

“Reaching this milestone marks an important step forward and opens new perspectives for the use of biological testing in clinical routine psychiatry,” said Prof. Eduard Vieta, Principal Investigator of the study.

The consortium, led by Alcediag with partners across Spain, Denmark, France, and Italy, received €2.5 million in co-funding from EIT Health. This milestone underscores both EIT Health’s mission to drive healthcare innovation and the consortium’s expertise in shaping the future of precision psychiatry.

Learn more about the impact EIT Health and EDIT-B are driving here.

Considering becoming an EIT Health member and want to share this example of pan-European collaboration with your colleagues? You can download the EDIT-B case study here.